Search Results for "vaccine, pneumococcal"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vaccine, pneumococcal. Results 21 to 26 of 26 total matches.

Expanded Table: Some Vaccines for Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
during or after 1980 without evidence of immunity (documentation of vaccination, laboratory evidence ...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e170-3 |  Show IntroductionHide Introduction

Belimumab (Benlysta) for Systemic Lupus Erythematosus

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2011  (Issue 1366)
-specific inhibitor, on functional antibodies to pneumococcal, tetanus, and influenza vaccines. Arthritis ...
Belimumab (Benlysta – Human Genome Sciences/GlaxoSmithKline) has been approved by the FDA for treatment of adults with active, autoantibody-positive, systemic lupus erythematosus (SLE). It is the first biologic agent approved for SLE and the first drug of any kind to be approved for this disease in >50 years.
Med Lett Drugs Ther. 2011 Jun 13;53(1366):45-6 |  Show IntroductionHide Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
; pharmacotherapy can be helpful. ▶ Influenza and pneumococcal vaccines are recommended to decrease the incidence ...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44   doi:10.58347/tml.2024.1710a |  Show IntroductionHide Introduction

Antibacterial Drugs for Community-Acquired Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021  (Issue 1616)
common causative bacterial pathogens. In the US, pneumococcal vaccination has substantially reduced ...
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Med Lett Drugs Ther. 2021 Jan 25;63(1616):10-5 |  Show IntroductionHide Introduction

Drugs for Common Bacterial Infections in Adults

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 2017  (Issue 1532)
monotherapy for empiric treatment of CAP could result in treatment failure in patients with pneumococcal ...
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse...
Med Lett Drugs Ther. 2017 Oct 23;59(1532):171-7 |  Show IntroductionHide Introduction

Drugs for Bacterial Infections

   
Treatment Guidelines from The Medical Letter • Jul 01, 2013  (Issue 131)
have anaerobic activity, are reasonable alternatives. In treating pneumococcal pneumonia due to strains ...
The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of susceptibility studies, clinical trials, and the opinions of Medical Letter reviewers. Tables 1 and 2 list the usual dosages of antibacterial drugs.
Treat Guidel Med Lett. 2013 Jul;11(131):65-74 |  Show IntroductionHide Introduction